Condition targeted | Final quality assessment criteria | ||||
---|---|---|---|---|---|
 | Medication quality category (MQ): Targeted prescribing | Associated PDRM event | Count | ||
 |  |  | App | NecDo | Total |
HYPERTENSION | MQ2: Selection of first line antihypertensives | CV events | - | 1 | 13 (25%) |
 | MQ3: Blood pressure control | CV events | 5 | 7 |  |
DIABETES | MQ1: Use of ACEI/ARB if micro-albuminuria | DM complications | - | 1 | 6 (12%) |
 | MQ2: Selection of metformin if overweight | DM complications | - | 1 |  |
 | MQ3: HbA1c control | DM complications | 2 | 2 |  |
AT RISK OF PRIMARY/SECONDARY VASCULAR EVENTS | MQ1: Use of antiplatelet or anticoagulant | CV events | 1 | 4 | 17 (33%) |
 | Use of statin | CV events | 1 | 3 |  |
 | Use of ACEI or ARB in CHD | CV events | 1 | 1 |  |
 | Use of beta blockers in CHD | CV events | - | 2 |  |
 | MQ4: Achievement of target statin dose | CV events | - | 4 |  |
CHRONIC HEART FAILURE | MQ1: Use of ACEI or ARB | CHF progression | - | 1 | 5(10%) |
 | Use of beta blocker | CHF progression | - | 1 |  |
 | MQ2: Selection of beta blocker licensed for CHF | CHF progression | 1 | - |  |
 | MQ4: Achievement of target ACEI/ARB dose | CHF progression | - | 1 |  |
 | Achievement of target BB dose | CHF progression | - | 1 |  |
ATRIAL FIBRILLATION | MQ1: Use of antiplatelet or anticoagulant | Stroke/Embolism | - | 3 | 4(8%) |
 | MQ2: Selection of warfarin in high risk of stroke | Stroke/Embolism | - | 1 |  |
ASTHMA | MQ1: Use of inhaled corticosteroid | Asthma exacerbation | 1 | 3 | 4 (8%) |
OSTEOPOROSIS | MQ1: Use of bone protecting agent | Fractures | - | 1 | 3(6%) |
 | Use of calcium/vitamin D supplement | Fractures | - | 2 |  |
Total | Â | Â | 12 | 40 | 52 (100%) |
Medication Quality categories | Â | ||||
1. INDICATION | MQ1: Need for treatment to control condition | 4 | 22 | 26 (52%) | |
2. SELECTION | MQ2: Selection of first line option within drug class | 1 | 3 | 4 (8%) | |
3. INTENSITY | MQ3: Achievement of intermediate outcome target | 7 | 9 | 16 (31%) | |
 | MQ4: Achievement of target dose | - | 6 | 6 (12%) | |
Criteria restricted to the elderly | |||||
Aged ≥ 75 |  |  | 4 | 4 | 8 (15%) |
Aged ≥ 80 |  |  | - | 2 | 2 (4%) |